Role of CD58 in minimal residual disease detection of ALL patients at South Egypt Cancer Institute
Mohammed, M., El- Ashmawy, H., Hashim, A., Sayed, D. (2020). Role of CD58 in minimal residual disease detection of ALL patients at South Egypt Cancer Institute. EKB Journal Management System, 31(4), 77-82. doi: 10.21608/mjmr.2022.217115
Mona I. Mohammed; Hossam El-Sayed A. El- Ashmawy; Alaa M. Hashim; Douaa M. Sayed. "Role of CD58 in minimal residual disease detection of ALL patients at South Egypt Cancer Institute". EKB Journal Management System, 31, 4, 2020, 77-82. doi: 10.21608/mjmr.2022.217115
Mohammed, M., El- Ashmawy, H., Hashim, A., Sayed, D. (2020). 'Role of CD58 in minimal residual disease detection of ALL patients at South Egypt Cancer Institute', EKB Journal Management System, 31(4), pp. 77-82. doi: 10.21608/mjmr.2022.217115
Mohammed, M., El- Ashmawy, H., Hashim, A., Sayed, D. Role of CD58 in minimal residual disease detection of ALL patients at South Egypt Cancer Institute. EKB Journal Management System, 2020; 31(4): 77-82. doi: 10.21608/mjmr.2022.217115

Role of CD58 in minimal residual disease detection of ALL patients at South Egypt Cancer Institute

Minia Journal of Medical Research
Volume 31, Issue 4, October 2020, Page 77-82  XML PDF (513.29 K)
Document Type: Original Article
DOI: 10.21608/mjmr.2022.217115
View on SCiNiTO View on SCiNiTO
Authors
Mona I. Mohammed1; Hossam El-Sayed A. El- Ashmawy2; Alaa M. Hashim2; Douaa M. Sayed3
1Department of Clinical pathology, General Hospital, Minia, Egypt
2Department of Clinical pathology, Faculty of Medicine, Al-Azhar University, Egypt
3Department of Clinical pathology, South Egypt Cancer Institute, Assiut University, Egypt
Abstract
Objective: To determine the role of CD58 marker in Minimal Residual Disease (MRD) 
monitoring in B-cell Precursor ALL patients at South Egypt Cancer Institute (SECI). 
Methodology: This study was carried out in Department of Clinical pathology, South Egypt 
Cancer Institute, from October 2017 to December 2019. We used SECI Flowcytometry lab 4 
color acute leukemia panel for diagnosis, then we studied the role of CD58 in detection of 
MRD by applied it twice; at diagnosis and at day21 (post induction). Results: 50 patients 
were included in our study with acute lymphoblastic leukemia (ALL) who underwent CBC, 
BM aspiration and immunophenotyping. The mean age was 9.14±5.53 years. It included 31
(62%) males and 19 (38%) females. MRD by CD58 was positive in 18 (36%) of patients 
while was negative in 32 (64%). CD58 show sensitivity of 100%, specificity of 97%, positive 
predictive value of 94.4% and negative predictive value of 100% whereas the overall 
diagnostic accuracy of CD58 in MRD detection in ALL patients was calculated to be 98%.
Conclusion: CD58 showed a high sensitivity to assess MRD in ALL patients, so its use to 
detect MRD in ALL is very useful.

Keywords
ALL; CD58; MRD 
Statistics
Article View: 100
PDF Download: 214